Skip to main content
Bioversys N logo

Bioversys N — Investor Relations & Filings

Ticker · BIOV ISIN · CH0210362643 LEI · 894500UFIGC75NPZEZ68 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2025-03-26 Earnings Release
Country CH Switzerland
Listing SW BIOV

About Bioversys N

https://www.bioversys.com/

Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.

Recent filings

Filing Released Lang Actions
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
Earnings Release Classification · 1% confidence The document is titled "BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024" and explicitly states it announces "audited financial results and corporate highlights for the full year 2024, as well as the publication of its 2024 Annual Report." It contains detailed financial tables (Operating income, Net loss, Cash & cash equivalents) covering the full fiscal year 2024, which is characteristic of an Annual Report (10-K equivalent for non-US filers, or a comprehensive annual financial disclosure). Although it is structured as an 'Ad hoc announcement pursuant to Art. 53 LR' (a regulatory filing format), the core content is the comprehensive annual financial summary and highlights, which aligns best with the 'Annual Report' definition (10-K). Since the document length is substantial (14,580 chars) and it contains the full financial details rather than just announcing the availability of the report, it is classified as the report itself. FY 2024
2025-03-26 English
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024
Earnings Release Classification · 1% confidence The document is an 'Ad hoc announcement' dated March 26, 2025, reporting 'CORPORATE HIGHLIGHTS AND KEY FINANCIALS FOR THE FULL YEAR 2024'. It explicitly states: 'BioVersys AG... announced today its audited financial results and corporate highlights for the full year 2024, as well as the publication of its 2024 Annual Report.' It contains detailed financial tables (FY 2024 vs FY 2023) and operational updates typical of an annual review. Although it mentions the publication of the Annual Report, the content provided is the press release summarizing the full-year results, which aligns best with an Earnings Release (ER) or a comprehensive report summary. Given the depth of financial data (income, loss, cash flow, balance sheet figures) and the focus on the full fiscal year results, it is more substantial than a typical ER (which is usually just highlights). However, since it explicitly announces the publication of the 'Annual Report 2024' and provides the full financial summary, it functions as the primary disclosure of the annual results. In many contexts, the press release accompanying the 10-K filing that details the full year's performance is classified as an Earnings Release (ER) if it's not the 10-K itself. Since the document is substantial (13,620 chars) and contains detailed audited results, it is classified as the primary disclosure of annual results, which is closest to the Annual Report (10-K) content, but since it is an announcement *about* the results and the Annual Report, and given the context of biotech reporting, it functions as the comprehensive Earnings Release/Report summary. Given the explicit mention of 'audited financial results' and the detailed financial table for the 'Full Year 2024', it is a comprehensive annual results disclosure. If the full 10-K document were present, that would be 10-K. As this is the detailed press release summarizing the full year's audited performance, ER is the most appropriate fit among the choices, as it contains the key financial figures for the year, even though it references the 10-K. It is too detailed for just an RPA or ER highlight. FY 2024
2025-03-26 English
BioVersys Annual Report 2024
Annual Report Classification · 1% confidence The document is titled 'ANNUAL REPORT 2024' and contains comprehensive sections including a Chairman and CEO letter, portfolio and pipeline analysis, and financial highlights. It provides detailed financial data for the fiscal year 2024, including profit and loss statements and balance sheet information. It is clearly the full annual report of BioVersys AG, not an announcement or a summary. FY 2024
2025-03-26 English
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
Legal Proceedings Report Classification · 1% confidence The document is explicitly labeled as an "Ad-hoc" announcement released pursuant to "Art. 53 LR" (likely a regulatory requirement for immediate disclosure). It announces a specific corporate event: the dosing of the first patient in a Phase 2 clinical trial for a drug candidate (alpibectir-ethionamide). This type of material, which provides timely, material, non-public information outside of scheduled financial reports, typically falls under general regulatory disclosure or news release categories. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements that do not fit other specific codes. It is not an Earnings Release (ER) as it discusses clinical trial progress, not financial results.
2025-03-20 English
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL
Legal Proceedings Report Classification · 1% confidence The document is explicitly labeled as an "Ad-hoc" announcement released pursuant to "Art. 53 LR" (likely a regulatory requirement for immediate disclosure). It announces a specific corporate event: the dosing of the first patient in a Phase 2 clinical trial for a drug candidate (alpibectir-ethionamide). This type of material, which provides timely, material, non-public information outside of scheduled financial reports, typically falls under general regulatory disclosure or news release categories. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements that do not fit other specific codes. It is not an Earnings Release (ER) as it discusses clinical trial progress, not financial results.
2025-03-19 English
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
Report Publication Announcement Classification · 1% confidence The document is a corporate announcement dated March 14, 2025, stating that BioVersys AG will publish its 'Full-Year 2024 financial results' on March 26, 2025. It also announces a subsequent conference call and webcast to discuss these results. Since the document itself is not the full financial report (10-K or IR) but rather an announcement about the *timing* of the report release and an associated event, it fits the definition of a Report Publication Announcement (RPA). The document length is short (3749 chars), supporting the 'MENU VS MEAL' rule, as it is announcing the availability of the main report rather than being the report itself.
2025-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.